Thomas Christely appointed CEO of Silence
This article was originally published in Scrip
Silence Therapeutics, a RNA interference therapeutics company, has appointed Thomas Christely CEO. Mr Christely joined Atugen AG, which later became Silence Therapeutics AG, in 2001 as CFO, and became COO in 2002 and CEO in 2006. He was instrumental in the merger of Silence Therapeutics AG with Silence Therapeutics plc (formerly SR Pharma).